NeoGenomics (NEO) Stephens Annual Investment Conference summary

Business performance and growth

• Clinical business saw strong growth with 15% volume and 18% revenue increases, offsetting pharma headwinds for 12% overall revenue growth in the quarter.

• NGS segment grew 24%, driven mainly by volume, with five key NGS products now representing 24% of clinical revenue and nearly a third of the portfolio.

• Expansion of the oncology sales team and rebranding under the PanTracer family have simplified messaging and driven further adoption.

• Pathline (NeoRamsey) integration completed, with a robust pipeline in the Northeast and expectations for accretive earnings starting in 2026.

• Focus is shifting from high-volume, low-value tests to higher-value, margin-accretive offerings.

Product innovation and portfolio strategy

• PanTracer LBx is expected to join the portfolio in 2025, with reimbursement upside possible but not critical to guidance.

• Early adoption of PanTracer Tissue and HRD is broad-based, aligning with national cancer incidence trends.

• EAP programs and clinical feedback have led to improvements in assay sensitivity, report structure, and turnaround time.

• Liquid CGP adoption is driven by actionable results, integration, and workflow efficiency for community oncologists.

• MRD segment re-entry with RaDaR ST is planned for early 2026, targeting head and neck (HPV negative) and breast cancer, with further indications in development.

Commercial and operational strategy

• Desiloing sales model uses data triangulation and AI to target mid-tier providers, doubling win rates and reducing sales cycles.

• Margin improvement initiatives include LIMS integration (benefits expected in late 2026–2027), lab automation, digital pathology, and RCM platform upgrades.

• Price increases and improved revenue cycle management are contributing to margin gains.

• M&A will be selective, focusing on tuck-in or bolt-on deals that fill portfolio gaps, with priority on organic growth and execution.